Agenus has enrolled the first patient in the BATTMAN Phase III trial, assessing BOT plus BAL in refractory, unresectable MSS or pMMR mCRC.
Actinogen has treated the first participant in the OLE segment of its Phase IIb/III pivotal XanaMIA AD trial after completion of 36 weeks in the randomised phase.
An analysis of 65,061 globally recruiting clinical trials across 186 countries finds that 4,361 studies, equivalent to 6.7% of all active trials, are impacted by disruption in the ...
Tempus' EHR-based alert system is designed to improve treatment equity and patient outcomes in cardiac valvular diseases like MR and AS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results